When does patent on eylea expire regeneron?

There isn’t a single “Eylea patent” with one expiry date. Eylea (aflibercept) is protected by multiple patent families (composition of matter, formulations, dosing/uses, etc.) and these patents expire at different times across different countries. In addition, there is regulatory data exclusivity for biologics (which can delay biosimilars even after patents expire), and that also varies by jurisdiction.

- In the U.S.: there are multiple patent families around aflibercept, plus the 12-year data exclusivity rule for biologics that can affect when a biosimilar could enter the market. Depending on the patent family, jurisdiction, and claim scope, expiration dates can range from a few years ago to the mid-2020s. The data exclusivity runs until roughly 12 years after FDA approval (Eylea was approved in 2011), which would be around 2023, but this does not guarantee a biosimilar can enter if patents are still in force or later challenges occur.

- In the EU and other markets: similar situation with multiple patents and varying data exclusivity terms (often 10–11 years of data exclusivity plus patent terms).

If you want a precise answer for a specific jurisdiction or a specific patent family (e.g., composition-of-matter patent in the U.S. or a use/formulation patent in the EU), I can look up the current public records and list the active patent families and their expiration dates.

What I need from you to tailor the answer:
- Do you want the U.S., EU, or another country’s patent status?
- Are you looking for the expiration of a specific patent family (composition of matter, use, formulation) or a general view of all Eylea-related patents?
- Do you want to include regulatory exclusivity (e.g., data exclusivity) in the timeline?

I can search public patent databases (Google Patents, USPTO, Espacenet, etc.) and summarize the current expiration dates and which patents (if any) are still in force in your jurisdiction. Note: I’m not providing legal advice—for patent clearance or litigation concerns, consult a patent attorney.